Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Exercise of Warrants

23 Jan 2019 16:31

RNS Number : 9256N
Motif Bio PLC
23 January 2019
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants 

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from warrant holders to exercise warrants representing 717,384 ordinary shares of 1p each ("Ordinary Shares") in the Company for total consideration of £152,626.80. The exercise price of warrants representing 642,384 Ordinary Shares was 20p per warrant. The exercise price of warrants representing 75,000 Ordinary Shares was 32.2 p per warrant.

 

Application has been made for the 717,384 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 29 January 2019. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 297,377,627 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

For further information please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

Peel Hunt LLP (NOMAD & BROKER)

+ 44 (0)20 7418 8900

Dr Christopher Golden

Oliver Jackson

Northland Capital Partners Limited (BROKER)

+44 (0)20 3861 6625

David Hignell/Vadim Alexandre/Rob Rees

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Helen Cresswell/Lianne Cawthorne

motifbio@walbrookpr.com

MC Services AG (EUROPEAN IR)

+49 (0) 89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

Solebury Trout (U.S. IR)

+ 1 (646) 378-2963

Meggie Purcell

mpurcell@troutgroup.com

Russo Partners (U.S. PR)

+1 (858) 717-2310 or +1 (212) 845 4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOELLFLRLFIVFIA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.